News|Articles|November 16, 2026

Aclaris' Bosakitug Misses Phase 2 Endpoints in Atopic Dermatitis

Listen
0:00 / 0:00

Key Takeaways

  • Bosakitug failed to demonstrate clinically meaningful efficacy on EASI at week 24 in phase 2 AD, despite being generally well tolerated.
  • Pharmacodynamic signals confirmed TSLP target engagement with reductions in Th1/Th2/Th17 immune activation biomarkers, yet without corresponding clinical improvement.
SHOW MORE

Bosakitug failed to meet primary and secondary endpoints in a phase 2 atopic dermatitis trial despite evidence of TSLP target engagement.

Aclaris Therapeutics announced that its investigational anti-thymic stromal lymphopoietin (TSLP) monoclonal antibody, bosakitug (ATI-045), failed to meet the primary and secondary endpoints in the phase 2 ADMIRATION trial evaluating patients with moderate to severe atopic dermatitis (AD). Despite the lack of clinical efficacy demonstrated in the trial, pharmacodynamic analyses showed evidence of TSLP target engagement and reductions in biomarkers associated with immune activation.

The primary endpoint evaluated the percentage change from baseline in Eczema Area and Severity Index (EASI) score at week 24. According to the company's November 16 announcement, the trial did not achieve this endpoint or its secondary endpoints. Bosakitug was generally well tolerated.

Phase 2 Results Highlight Challenges With TSLP Inhibition

Bosakitug is a humanized monoclonal antibody designed to inhibit TSLP, an epithelial-derived cytokine involved in initiating and amplifying inflammatory responses. TSLP contributes to type 2 inflammation, a central component of AD pathogenesis, making it a potential therapeutic target for patients with moderate-to-severe disease.

Although the ADMIRATION trial did not demonstrate sufficient clinical efficacy to meet its prespecified endpoints, pharmacodynamic findings indicated biological activity. Investigators observed robust TSLP target engagement alongside downregulation of biomarkers associated with T-helper (Th) 1, Th2, and Th17 immune responses.

These findings suggest that bosakitug affected inflammatory signaling pathways without producing the clinical improvements necessary to meet the study's efficacy endpoints. The results also underscore the challenges of targeting TSLP alone in AD, where multiple inflammatory pathways contribute to disease activity.

Aclaris did not provide detailed numerical efficacy results, treatment-group comparisons, or adverse event rates in its top-line announcement.

Aclaris Reaffirms Development Priorities

Following the ADMIRATION results, Aclaris emphasized that its broader development strategy remains unchanged, with continued investment in oral kinase inhibitors and its investigational bispecific antibody ATI-052.

The company has initiated a phase 2b trial of modzatinib (ATI-2138), an oral inhibitor of interleukin-2-inducible T-cell kinase (ITK) and Janus kinase 3 (JAK3), in patients with lichen planus. The investigational therapy targets signaling pathways involved in T-cell activation and inflammatory responses.

Aclaris also reported completing investigational new drug (IND)-enabling studies for ATI-9494, an investigational oral ITK/TXK inhibitor, with plans to submit an IND application during the fourth quarter of 2026.

Additionally, the company intends to initiate a phase 2b trial of ATI-052, an investigational bispecific antibody targeting TSLP and the interleukin-4 receptor alpha (IL-4Rα), in eosinophilic esophagitis during the first quarter of 2027.

Unlike bosakitug, which targets TSLP alone, ATI-052 is designed to inhibit 2 inflammatory signaling pathways. Its dual-targeting mechanism represents a different therapeutic approach, although further clinical studies are needed to establish its efficacy and safety.

Implications for the Atopic Dermatitis Pipeline

The ADMIRATION findings add to ongoing questions surrounding the clinical utility of TSLP inhibition as a standalone therapeutic strategy in AD. Although the observed pharmacodynamic activity supports engagement of the intended biological target, the failure to achieve clinical endpoints demonstrates that biomarker changes do not necessarily translate into meaningful improvements in disease severity.

For clinicians, the results reinforce the importance of evaluating investigational therapies through clinically relevant outcomes, including changes in disease severity, symptom burden, and treatment tolerability.

Aclaris has not announced additional development plans for bosakitug following the phase 2 results. The company expects several clinical and regulatory milestones involving its remaining investigational therapies throughout 2027.

References

  1. Aclaris Therapeutics announces top line phase 2 results for its anti-TSLP monoclonal antibody bosakitug (ATI-045) in atopic dermatitis (AD). News release. Aclaris Therapeutics. November 16, 2026. Accessed November 16, 2026. https://investor.aclaristx.com/news-releases/news-release-details/aclaris-therapeutics-announces-top-line-phase-2-results-its-anti
  2. Aclaris Therapeutics, Inc. Current report on Form 8-K. US Securities and Exchange Commission. November 16, 2026. https://www.sec.gov/Archives/edgar/data/1557746/000110465926127478/acrs-20261116x8k.htm

Related to this article

Journal Digest: November 16
Recent dermatology research explores chronic hand eczema prevalence, cancer risk in morphea, pernio, biologic optimization in HS, and melanoma risk prediction.